Development of an RNA Expression Platform Controlled by Viral Internal Ribosome Entry Sites
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Since 1990, many nucleic acid expression platforms consisting of DNA or RNA have been developed. However, although RNA expression platforms have been relatively neglected, several such platforms capped at the 5’ end of RNA by an anti-reverse cap analog have now been developed. At the same time, the capping reaction is a bottleneck in the production of such platforms, with high cost and low efficiency. Here, we investigated several viral and eukaryotic internal ribosome entry sites (IRESs) to develop an optimal RNA expression platform, because IRES-dependent translation does not require a capping step. RNA expression platforms constructed with IRESs from the 5’ untranslated regions of the encephalomyocarditis virus (EMCV) and the intergenic region of the cricket paralysis virus (CrPV) showed sufficient expression efficiency compared with cap-dependent RNA expression platforms. However, eukaryotic IRESs exhibited a lower viral IRES expression efficiency. Interestingly, the addition of a poly(A) sequence to the 5’ end of the coxsackievirus B3 (CVB3) IRES (pMA-CVB3) increased the expression level compared with the CVB3 IRES without poly(A) (pCVB3). Therefore, we developed two multiexpression platforms (termed pMA-CVB3-EMCV and pCrPV-EMCV) by combining the IRESs of CVB3, CrPV, and EMCV in a single-RNA backbone. The pMA-CVB3-EMCV-derived RNA platform showed the highest expression level. Moreover, it clearly exhibited expression in mouse muscles in vivo. These RNA expression platforms prepared using viral IRESs will be useful in developing potential RNA-based prophylactic or therapeutic vaccines, because they have better expression efficiency and do not need a capping step.
Abstract
Since 1990, many nucleic acid expression platforms consisting of DNA or RNA have been developed. However, although RNA expression platforms have been relatively neglected, several such platforms capped at the 5’ end of RNA by an anti-reverse cap analog have now been developed. At the same time, the capping reaction is a bottleneck in the production of such platforms, with high cost and low efficiency. Here, we investigated several viral and eukaryotic internal ribosome entry sites (IRESs) to develop an optimal RNA expression platform, because IRES-dependent translation does not require a capping step. RNA expression platforms constructed with IRESs from the 5’ untranslated regions of the encephalomyocarditis virus (EMCV) and the intergenic region of the cricket paralysis virus (CrPV) showed sufficient expression efficiency compared with cap-dependent RNA expression platforms. However, eukaryotic IRESs exhibited a lower viral IRES expression efficiency. Interestingly, the addition of a poly(A) sequence to the 5’ end of the coxsackievirus B3 (CVB3) IRES (pMA-CVB3) increased the expression level compared with the CVB3 IRES without poly(A) (pCVB3). Therefore, we developed two multiexpression platforms (termed pMA-CVB3-EMCV and pCrPV-EMCV) by combining the IRESs of CVB3, CrPV, and EMCV in a single-RNA backbone. The pMA-CVB3-EMCV-derived RNA platform showed the highest expression level. Moreover, it clearly exhibited expression in mouse muscles in vivo. These RNA expression platforms prepared using viral IRESs will be useful in developing potential RNA-based prophylactic or therapeutic vaccines, because they have better expression efficiency and do not need a capping step.
참고문헌 (50)
- Wolff JA, "Direct gene transfer into mouse muscle in vivo", Science, 247, pp.1465~1468 (1990)
- Marć MA, "Nucleic acid vaccination strategies against infectious diseases", Expert. Opin. Drug Deliv, 12, pp.1851~1865 (2015)
- Sahin U, "mRNA-based therapeutics—developing a new class of drugs", Nat. Rev. Drug Discov, 13, pp.759~780 (2014)
- Kallen KJ, "A development that may evolve into a revolution in medicine : mRNA as the basis for novel, nucleotide-based vaccines and drugs", Ther. Adv. Vaccines, 2, pp.10~31 (2014)
- Probst J, "Gene vaccines", pp.223~245 (2012), Springer Verlag
- Kallen KJ, "A novel, disruptive vaccination technology: self-adjuvanted RNActive vaccines", Hum. Vaccin. Immunother, 9, pp.2263~2276 (2013)
- Fotin-Mleczek M, "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", J. Gene Med, 14, pp.428~439 (2012)
- Geall AJ, "RNA: The new revolution in nucleic acid vaccines", Semin. Immunol, 25, pp.152~159 (2013)
- Schlake T, "Developing mRNA-vaccine technologies", RNA Biol, 9, pp.1319~1330 (2012)
- Iavarone C, "Mechanism of action of mRNA-based vaccines", Expert. Rev. Vaccines, 16, pp.871~881 (2017)
- Akhrymuk I, "Evasion of the innate immune response: the Old World alphavirus nsP2protein induces rapid degradation of Rpb1, a catalytic subunit of RNA polymerase II", J. Virol, 86, pp.7180~7191 (2012)
- Hollidge BS, "The role of interferon antagonist, non-structural proteins in the pathogenesis and emergence of arboviruses", Viruses, 3, pp.629~658 (2011)
- Blakqori G, "La Crosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts", J. Virol, 81, pp.4991~4999 (2007)
- Ngoi SM, "Exploiting internal ribosome entry sites in gene therapy vector design", Curr. Gene Ther, 4, pp.15~31 (2004)
- Mailliot J, "Viral internal ribosomal entry sites: four classes for one goal", Wiley Interdiscip Rev. RNA, 9, pp.e1458~ (2018)
- Yamamoto H, "Ribosomal chamber music : toward an understanding of IRES mechanisms", Trends Biochem. Sci, 42, pp.655~668 (2017)
- Pelletier J, "Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA", Nature, 334, pp.320~325 (1988)
- Kieft JS, "Viral IRES RNA structures and ribosome interactions", Trends Biochem. Sci, 33, pp.274~283 (2008)
- Murray J, "Structural characterization of ribosome recruitment and translocation by type IV IRES", Elife, 5, pp.e13567~ (2016)
- 조아라, "Ethical Guidelines for Use of Experimental Animals in Biomedical Research", Journal of Bacteriology and Virology, 43(1), pp.18~26 (2013), 대한미생물학회[DOI]
- Wong ET, "Improved co-expression of multiple genes in vectors containing internal ribosome entry sites(IRESes)from human genes", Gene Ther, 9, pp.337~344 (2002)
- Chiang PW, "The 5¢-untranslated region of the FMR1 message facilitates translation by internal ribosome entry", J. Biol. Chem, 276, pp.37916~37921 (2001)
- Filley CM, "White matter disease and cognitive impairment in FMR1 premutation carriers", Neurology, 84, pp.2146~2152 (2015)
- Schiavi A, "Connexin43 mRNA contains a functional internal ribosome entry site", FEBS Lett, 464, pp.118~122 (1999)
- Bernstein J, "PDGF2", c-sis mRNA leader contains a differentiation-linked internal ribosomal entry site(D-IRES), 1997, pp.272, 9356~9362
- Huez I, "Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA", Mol. Cell Biol, 18, pp.6178~6190 (1998)
- Goodfellow I, "The genome-linked protein VPg of vertebrate viruses—a multifaceted protein", Curr. Opin. Virol, 1, pp.355~362 (2011)
- Sean P, "Coxsackievirus B RNA replication : lessons from poliovirus", Curr. Top. Microbiol. Immunol, 323, pp.89~121 (2008)
- Langereis MA, "Modification of picornavirus genomic RNA using ‘click’chemistry shows that unlinking of the VPg peptide is dispensable for translation and replication of the incoming viral RNA", Nucleic Acids Res, 42, pp.2473~2482 (2014)
- Sköld AE, "Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets", Cancer Immunol. Immunother, 64, pp.1461~1473 (2015)
- Scheel B, "Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA", Eur. J. Immunol, 35, pp.1557~1566 (2005)
- Petsch B, "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection", Nat. Biotechnol, 30, pp.1210~1216 (2012)
- Richner JM, "Modified mRNA vaccines protect against Zika virus infection", Cell, 169, pp.176~ (2017)
- Avogadri F, "Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity", PLoS One, 5, pp.e12670~ (2010)
- Seregin SS, "Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy", Mol. Ther, 17, pp.685~696 (2009)
- Pyankov OV, "A Kunjin replicon viruslike particle vaccine provides protection against Ebola virus infection in nonhuman primates", J. Infect. Dis, 212(Suppl 2), pp.S368~S371 (2015)[DOI]
- Schnee M, "An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs", PLoS Negl. Trop. Dis, 10, pp.e0004746~ (2016)
- Brito LA, "A cationic nanoemulsion for the delivery of nextgeneration RNA vaccines", Mol. Ther, 22, pp.2118~2129 (2014)
- Bahl K, "Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses", Mol. Ther, 25, pp.1316~1327 (2017)
- Alberer M, "Safety and immunogenicity of a mRNA rabies vaccine in healthy adults : an open-label, nonrandomised, prospective, first-in-human phase 1 clinical trial", Lancet, 390, pp.1511~1520 (2017)
- Youn H, "Modified mRNA as an a lternative to plasmid DNA(pDNA)for transcript replacement and vaccination therapy", Expert. Opin. Biol. Ther, 15, pp.1337~1348 (2015)
- Diken M, "mRNA : A versatile molecule for cancer vaccines", Curr. Issues Mol. Biol, 22, pp.113~128 (2017)
- Kranz LM, "Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy", Nature, 534, pp.396~401 (2016)
- Dickson KA, "Ribonuclease inhibitor : structure and function", Prog. Nucleic Acid. Res Mol. Biol, 80, pp.349~374 (2005)
- Geall AJ, "Nonviral delivery of self-amplifying RNA vaccines", Proc. Natl. Acad. Sci. USA, 109, pp.14604~14609 (2012)
- Bettinger T, "Peptide-mediated RNA delivery : a novel approach for enhanced transfection of primary and post-mitotic cells", Nucleic Acids Res, 29, pp.3882~3891 (2001)
- Leppek K, "Functional 5¢ UTR mRNA structures in eukaryotic translation regulation and how to find them", Nat. Rev. Mol. Cell Biol, 19, pp.158~174 (2018)
- Simoes EA, "An RNA hairpin at the extreme 5’ end of the poliovirus RNA genome modulates viral translation in human cells", J. Virol, 65, pp.913~921 (1991)
- Andino R, "A functional ribonucleoprotein complex forms around the 5’ end of poliovirus RNA", Cell, 63, pp.369~380 (1990)
- Herold J, "Poliovirus requires a precise 5’end for efficient positive-strand RNA synthesis", J. Virol, 74, pp.6394~6400 (2007)